2024
Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
McCoy R, Herrin J, Swarna K, Deng Y, Kent D, Ross J, Umpierrez G, Galindo R, Crown W, Borah B, Montori V, Brito J, Neumiller J, Mickelson M, Polley E. Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. Nature Cardiovascular Research 2024, 3: 431-440. PMID: 38846711, PMCID: PMC11156225, DOI: 10.1038/s44161-024-00453-9.Peer-Reviewed Original ResearchAdverse cardiovascular eventsGlucose-lowering medicationsType 2 diabetesCardiovascular diseaseGLP-1RACardiovascular eventsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsRetrospective cohort studyCardiovascular disease risk reductionGlucose-lowering agentsModerate cardiovascular riskCardiovascular risk reductionReceptor agonistsEffects of glucose-lowering medicationsRisk reductionCardiovascular riskCohort studyCardiovascular outcomesHigh riskBaseline riskModerate risk
2021
Age‐Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011–2018
Rhee TG, Kumar M, Ross JS, Coll PP. Age‐Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011–2018. Journal Of The American Geriatrics Society 2021, 69: 1272-1282. PMID: 33598936, PMCID: PMC9869399, DOI: 10.1111/jgs.17038.Peer-Reviewed Original ResearchConceptsUse of aspirinStatin useAspirin useCardiovascular riskSecondary preventionMedication usePrimary preventionAge-related trajectoriesAge 50Prevention treatmentAngina/angina pectorisLow-dose aspirin dailyLong-term statin useOlder adultsDaily aspirin usePrimary prevention treatmentSecondary prevention treatmentSubsequent CVD eventsFirst cardiovascular eventCoronary heart diseaseAdults Aged 50Nutrition Examination SurveyCross-sectional studyHealth Interview SurveyNon-institutionalized adults
2020
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. The BMJ 2020, 368: l7078. PMID: 32024657, PMCID: PMC7190063, DOI: 10.1136/bmj.l7078.Peer-Reviewed Original ResearchConceptsIndividual patient-level dataCardiovascular related deathsCardiovascular riskMyocardial infarctionRelated deathsSummary-level dataHeart failureOdds ratioSystematic reviewIncreased cardiovascular riskMore myocardial infarctionsHeart failure eventsCochrane Central RegistryAcute myocardial infarctionMyocardial infarction eventsPatient-level dataRandom-effects modelWeb of ScienceAnalysis of trialsEligible trialsComposite outcomeAdverse eventsContinuity correctionControlled TrialsRosiglitazone treatment
2018
Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population
Warner F, Dhruva SS, Ross JS, Dey P, Murugiah K, Krumholz HM. Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population. BMJ Open 2018, 8: e021685. PMID: 30037874, PMCID: PMC6059296, DOI: 10.1136/bmjopen-2018-021685.Peer-Reviewed Original ResearchConceptsSystolic Blood Pressure Intervention TrialFramingham risk scoreCardiovascular riskRisk scoreStudy populationStudy participantsNon-diabetic adultsTotal study populationHigh-risk populationClinical trial dataClinical trial sitesTrial populationIntervention trialsRisk populationsNew England JournalIndependent investigatorsTrial dataSecondary analysisSPRINT trialSPRINT dataTrialsRiskScoresParticipantsPopulation
2017
Association between FDA black box warnings and Medicare formulary coverage changes.
Dhruva SS, Karaca-Mandic P, Shah ND, Shaw DL, Ross JS. Association between FDA black box warnings and Medicare formulary coverage changes. The American Journal Of Managed Care 2017, 23: e310-e315. PMID: 29087169.Peer-Reviewed Original ResearchConceptsFDA black box warningBlack box warningNew black box warningsBox warningCardiovascular riskDrug alternativesNew safety informationMajority of drugsFormulary changeRetrospective analysisFormulary coverageFormularyDrugsCapsule formulationSubstantial proportionMedicationsDeathRiskSafety informationFDAYears
2014
Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature: A Cross-Sectional Analysis
Downing NS, Cheng T, Krumholz HM, Shah ND, Ross JS. Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature: A Cross-Sectional Analysis. JAMA Internal Medicine 2014, 174: 1176-1182. PMID: 24796406, PMCID: PMC4124903, DOI: 10.1001/jamainternmed.2014.1371.Peer-Reviewed Original ResearchConceptsACCORD lipid trialACCORD-LipidFibrate useTrial interpretationImproved cardiovascular outcomesCross-sectional studyCross-sectional analysisStatin therapyCardiovascular outcomesCardiovascular riskDiabetes (ACCORD) trialDiabetes mellitusConflicts of interestTrialsPatientsFenofibrateAuthor conflictsLipid componentsMellitusTherapyPhysiciansMonths
2011
Use of Fibrates in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of Fibrates in the United States and Canada. JAMA 2011, 305: 1217-1224. PMID: 21427374, PMCID: PMC3332101, DOI: 10.1001/jama.2011.353.Peer-Reviewed Original ResearchMeSH KeywordsCanadaCardiovascular DiseasesCohort StudiesCosts and Cost AnalysisDiabetes Mellitus, Type 2Drug CostsDrugs, GenericFenofibrateFibric AcidsHealth ExpendituresHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMedical AuditPractice Patterns, Physicians'PrescriptionsUnited StatesConceptsUse of fibratesRole of fibratesObservational cohort studyIMS Health dataFenofibrate useCardiovascular riskCohort studyDiabetes (ACCORD) trialClinical benefitFibratesMonthsPrescriptionUnited StatesPatientsNegative resultsFenofibrateHealth dataCurrent useGeneric formulationPopulationStatinsTherapyTrials
2009
Determinants of Cardiac Catheterization Use in Older Medicare Patients With Acute Myocardial Infarction
Ko DT, Ross JS, Wang Y, Krumholz HM. Determinants of Cardiac Catheterization Use in Older Medicare Patients With Acute Myocardial Infarction. Circulation Cardiovascular Quality And Outcomes 2009, 3: 54-62. PMID: 20123672, PMCID: PMC3024143, DOI: 10.1161/circoutcomes.109.858456.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overCardiac CatheterizationChi-Square DistributionComorbidityFemaleHemorrhageHospitalizationHumansLikelihood FunctionsLogistic ModelsMaleMedicareMyocardial InfarctionPatient SelectionPractice Patterns, Physicians'Risk AssessmentRisk FactorsSeverity of Illness IndexSex FactorsTime FactorsTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionCardiac catheterization useCardiac catheterizationInappropriate indicationsAMI patientsAppropriate indicationsMyocardial infarctionRisk scoreCardiology/American Heart Association class IBaseline cardiovascular riskOlder Medicare patientsHigh-risk patientsDemographic factorsMore comorbiditiesCardiovascular riskOlder patientsMale sexProcedure indicationFemale sexMedicare patientsAmerican CollegeAMI admissionsMedicare feePatientsCatheterizationPooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance. JAMA Internal Medicine 2009, 169: 1976-1985. PMID: 19933959, PMCID: PMC2830805, DOI: 10.1001/archinternmed.2009.394.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsCardiovascular SystemCyclooxygenase 2 InhibitorsDrug IndustryHumansIncidenceLactonesMyocardial InfarctionRandomized Controlled Trials as TopicRisk AssessmentSafety-Based Drug WithdrawalsSulfonesTime FactorsUnited StatesUnited States Food and Drug AdministrationConceptsPlacebo-controlled trialVoluntary market withdrawalAdverse eventsCardiovascular riskThromboembolic adverse eventsMain outcome measurementsClinical trial dataRofecoxib groupOutcome measurementsTrial dataPlaceboTrial durationSafety surveillanceTrialsMarket withdrawalDeathRiskP-valueSurveillance effortsSubjectsWithdrawalRofecoxibYearsIncidenceDose